Mel Mann, World’s Longest Living Gleevec (Imatinib) and Tyrosine Kinase Inhibitor Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared on X by Stanford Medicine, adding:
“This is the kind of research that matters. Stanford scientists are engineering immune cells to follow the metabolic ‘scent’ cancer leaves behind – turning them into bloodhounds that can better track and infiltrate solid tumors.
For patients, the difference between a treatment that stays in the bloodstream and one that actually reaches the tumor can mean everything. Still early. Still in mice. But this is the direction we need: smarter cells, better targeting, fewer dead ends.
Precision medicine isn’t just a slogan when you’re living it. Keep funding the work that gives survivors a real shot.”
Quoting Stanford Medicine:
“Researchers at Stanford Medicine are developing immune cells designed to better recognize and attack cancer – offering a new approach to cancer treatment.
You can also read: CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment
Other articles featuring Mel Mann on OncoDaily.